Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home Companiesgenedrive plc

genedrive plc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
1.05 GBX 0.03 ( 2.44%)
Last update at 2026-10-27T15:56:00Z
VOLUME
2469562
Market Cap
15.25M

Momentum Score

…

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.94
Low
1.05
High
52 Week Price Range
0.19
Low
1.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.02
Dividend Yield
-
Revenue TTM
1.17M
Revenue Per Share
0.00
Gross Profit TTM
-3.33M
Debt / Equity
0.00
ROE
-402.49%
Net Debt
-1.18M
ROCE
-377.33%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -5.43M -7.75M -5.98M -5.63M -1.85M
Net income -5.23M -7.08M -5.15M -4.67M -0.69M
Selling general administrative 2.10M 1.64M 1.35M 1.79M 1.66M
Gross profit 0.76M 0.25M 0.06M -3.82M -3.82M
Reconciled depreciation 0.07M 0.25M 0.25M 0.25M 0.25M
Ebit -5.43M -7.74M -5.19M -5.62M -5.48M
Ebitda -5.36M -7.49M -4.94M -5.37M -5.24M
Depreciation and amortization 0.07M 0.25M 0.25M 0.25M 0.25M
Operating income -5.38M -5.31M -5.19M -5.62M -5.48M
Other operating expenses 6.33M 5.81M 5.28M 5.66M 6.17M
Interest expense 0.00M 0.01M 0.03M 0.02M 0.23M
Tax provision -0.20M -0.68M -0.83M -0.96M -1.16M
Interest income 0.04M 0.03M 0.03M 0.00M 0.00M
Net interest income -0.05M -0.55M -0.00M -0.02M -0.23M
Income tax expense -0.20M -0.68M -0.83M -0.96M -1.16M
Total revenue 0.76M 0.50M 0.06M 0.05M 0.69M
Total operating expenses 6.14M 5.81M 5.28M 5.66M 6.17M
Cost of revenue - 0.25M - 3.87M 4.51M
Total other income expense net -0.05M -2.44M -0.79M -0.02M 3.63M
Net income from continuing ops -5.23M -7.08M -5.15M -4.67M -0.69M
Net income applicable to common shares - - - -4.67M -0.69M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 2.81M 6.80M 4.51M 6.62M 4.88M
Other current assets - 0.93M - 1.08M 1.40M
Total liab 1.38M 1.44M 2.47M 1.01M 1.28M
Total stockholder equity 1.44M 5.36M 2.04M 5.61M 3.59M
Other current liab 0.79M 0.76M 1.29M 0.84M 0.85M
Common stock 9.37M 8.15M 1.49M 1.39M 0.95M
Capital stock 9.37M 8.15M 1.49M 1.39M 0.95M
Retained earnings -65.17M -57.44M -52.22M -47.07M -42.36M
Other assets - - - - 0.05M
Cash 1.18M 5.19M 2.60M 4.59M 2.57M
Total current liabilities 1.38M 1.44M 2.45M 1.01M 1.28M
Current deferred revenue - - - -0.84M -0.85M
Net debt -1.18M -5.17M -2.36M -4.57M -2.46M
Short term debt - 0.02M 0.22M 0.02M 0.12M
Short long term debt total - 0.02M 0.24M 0.02M 0.12M
Other stockholder equity 54.73M 54.66M 52.78M 45.68M 41.41M
Property plant equipment - - - 0.21M 0.30M
Total current assets 2.69M 6.63M 4.12M 6.42M 4.53M
Net tangible assets - - - 5.61M 3.59M
Net receivables 1.07M 0.12M 0.16M 1.06M 1.32M
Inventory 0.43M 0.38M 0.53M 0.75M 0.56M
Accounts payable 0.59M 0.67M 0.94M 0.99M 1.17M
Accumulated other comprehensive income 2.50M - - - -
Non currrent assets other - - - -0.21M -0.30M
Non current assets total 0.13M 0.17M 0.39M 0.21M 0.35M
Capital lease obligations 0.00M 0.02M 0.24M 0.02M 0.12M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - 0.00M -0.01M 0.03M 0.00M
Change to liabilities - - - -0.29M -1.03M
Total cashflows from investing activities -0.02M 0.00M - 0.03M 0.00M
Net borrowings - - - -0.12M -0.50M
Total cash from financing activities 1.12M 6.36M 1.82M 6.58M -0.46M
Net income -5.43M -5.31M -5.22M -5.62M -5.48M
Change in cash -4.01M 2.59M -1.99M 2.02M -5.64M
Begin period cash flow 5.19M 2.60M 4.59M 2.57M 8.22M
End period cash flow 1.18M 5.19M 2.60M 4.59M 2.57M
Total cash from operating activities -5.10M -3.77M -3.81M -4.59M -5.15M
Issuance of capital stock 1.23M 6.25M 1.69M 6.69M 0.05M
Depreciation 0.07M 0.25M 0.25M 0.25M 0.25M
Other cashflows from investing activities - 0.03M - 0.09M 0.10M
Change to inventory -0.05M 0.14M 0.22M -0.19M -0.14M
Change to account receivables -0.30M -0.22M - 0.05M 0.24M
Other cashflows from financing activities -0.02M 0.11M 0.14M -0.12M -0.14M
Change to netincome - - - 0.26M -3.59M
Capital expenditures 0.02M 0.03M 0.05M 0.06M 0.10M
Change in working capital -0.39M 0.41M 0.11M -0.43M -0.93M
Stock based compensation 0.08M 0.06M 0.10M 0.04M 0.00M
Other non cash items 0.56M 0.83M 0.96M -0.17M -0.01M
Free cash flow -5.12M -3.80M -3.86M -4.66M -5.26M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GDR
genedrive plc		 0.03
2.44%		 1.05 - 12.38 12.99 10.61 16.54 -6.05
IDHC
Integrated Diagnostics Holdings PLC		 -
-%		 0.48 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 -
-%		 5.55 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -
-%		 9.00 - 53.19 2.19 3.19 1.81 -0.25
CLBX
CelLBxHealth plc		 -
-%		 0.60 - - 7.05 1.50 6.07 -1.62

Profile*

genedrive plc

genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.

The Incubator Building, Manchester, United Kingdom, M13 9XX

44 16 1989 0245

https://www.genedriveplc.com

43

Name Title Year Born
Mr. David Budd CEO & Exec. Director 1968
Mr. Russell John Shaw Chief Financial Officer & Director 1978
Dr. Gino Miele Ph.D. CEO, Chief Scientific Officer & Executive Director 1970
Mr. Russell John Shaw CFO, Secretary & Director 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…